CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 327 enrolled
Drug / intervention
CP-690,550 +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00784719
NCT00784719Phase 2Completed
CompareCT.gov

A Phase I/II Prospective, Randomized, Double Masked, Vehicle And Comparator Controlled, Dose Ranging Study Of CP-690,550 In Subjects With Dry Eye Disease.

Pfizer·interventional·Posted Nov 4, 2008·Updated Apr 9, 2013

In Brief

A Phase 2 clinical trial evaluating CP-690,550, Cyclosporine, and 1 other intervention for Dry Eye Syndromes. Completed, enrolled 327 participants across 27 sites.

Detailed Summary

A prospective, randomized, placebo and active comparator controlled study of CP-690,550 in subjects with dry eye.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye Syndromes
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 4, 2008
Enrollment StartNov 1, 2008
Primary CompletionOct 1, 2009
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 17.7 years ago

Interventions

CP-690,550drug

Ophthalmic topical solution, low dose, dosed at least once/day, 8 weeks

CP-690,550drug

Ophthalmic topical solution, medium dose, dosed at least once/day, 8 weeks

CP-690,550drug

Ophthalmic topical solution, intermediate dose, dosed at least once/day, 8 weeks

CP-690,550drug

Ophthalmic topical solution, high dose, dosed at least once/day, 8 weeks

Cyclosporinedrug

Ophthalmic topical solution, 0.05%, dosed at least once/day, 8 weeks

CP-690,550 Vehicledrug

Ophthalmic topical solution, dosed at least once/day, 8 weeks